Alimera Sciences, Inc.
(NASDAQ : ALIM)

( )
ALIM PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
IMMUImmunomedics, Inc. -0.26%85.0311.0%$728.04m
MRNAModerna, Inc. 0.33%70.750.0%$670.05m
AMGNAmgen, Inc. 2.36%254.161.3%$669.90m
ILMNIllumina, Inc. 1.17%309.083.5%$646.09m
NVAXNovavax, Inc. 0.37%108.3596.5%$600.09m
GILDGilead Sciences, Inc. 1.76%63.191.0%$591.39m
REGNRegeneron Pharmaceuticals, Inc. -2.41%559.782.7%$463.31m
VRTXVertex Pharmaceuticals, Inc. 0.67%272.121.9%$349.26m
BIIBBiogen, Inc. 0.47%283.681.6%$346.64m
SRNESorrento Therapeutics, Inc. -3.88%11.151.4%$316.35m
EXASEXACT Sciences Corp. -0.06%101.9520.7%$266.37m
ALXNAlexion Pharmaceuticals, Inc. 1.75%114.432.0%$262.90m
SGENSeattle Genetics, Inc. 2.48%195.696.0%$235.67m
VXRTVaxart, Inc. -2.56%6.650.0%$191.96m
MNTAMomenta Pharmaceuticals, Inc. -0.02%52.483.0%$191.71m

Company Profile

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.